ATE152629T1 - Diagnose von krebs-metastasen durch das mts-1 gen - Google Patents

Diagnose von krebs-metastasen durch das mts-1 gen

Info

Publication number
ATE152629T1
ATE152629T1 AT91915859T AT91915859T ATE152629T1 AT E152629 T1 ATE152629 T1 AT E152629T1 AT 91915859 T AT91915859 T AT 91915859T AT 91915859 T AT91915859 T AT 91915859T AT E152629 T1 ATE152629 T1 AT E152629T1
Authority
AT
Austria
Prior art keywords
mts
present
diagnosis
gene
protein
Prior art date
Application number
AT91915859T
Other languages
English (en)
Inventor
Sayeeda Zain
Eugene Lukanidin
Original Assignee
Res Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Corp Technologies Inc filed Critical Res Corp Technologies Inc
Application granted granted Critical
Publication of ATE152629T1 publication Critical patent/ATE152629T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4728—Calcium binding proteins, e.g. calmodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AT91915859T 1990-07-09 1991-07-09 Diagnose von krebs-metastasen durch das mts-1 gen ATE152629T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55060090A 1990-07-09 1990-07-09

Publications (1)

Publication Number Publication Date
ATE152629T1 true ATE152629T1 (de) 1997-05-15

Family

ID=24197845

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91915859T ATE152629T1 (de) 1990-07-09 1991-07-09 Diagnose von krebs-metastasen durch das mts-1 gen

Country Status (7)

Country Link
EP (1) EP0566571B1 (de)
JP (2) JP3398149B2 (de)
AT (1) ATE152629T1 (de)
CA (1) CA2086829A1 (de)
DE (1) DE69126038T2 (de)
DK (1) DK0566571T3 (de)
WO (1) WO1992000757A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700444A (en) * 1992-02-20 1997-12-23 Rhomed Incorporated Chemotactic peptide pharmaceutical applications
US5443816A (en) * 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
US6638504B1 (en) * 1990-07-09 2003-10-28 Research Corporation Technologies, Inc. Methods for treating cancer
US5798257A (en) * 1990-07-09 1998-08-25 Research Corporation Technologies, Inc. Nucleic acid encoding human MTS-1 protein
US5556609A (en) * 1992-02-20 1996-09-17 Rhomed Incorporated YIGSR peptide radiopharmaceutical applications
GB9311130D0 (en) * 1993-05-28 1993-07-14 Isis Innovation Tumor metastasis gene
AU685627B2 (en) * 1994-03-18 1998-01-22 Myriad Genetics, Inc. Germline mutations in the MTS gene and method for detecting predisposition to cancer at the MTS gene
AU694502B2 (en) * 1994-03-18 1998-07-23 Myriad Genetics, Inc. Mts gene, mutations therein, and methods for diagnosing cancer using mts gene sequence
US5872007A (en) * 1995-02-17 1999-02-16 Hybridon, Inc. CAPL-specific oligonucleotides and methods of inhibiting metastatic cancer
WO1996039504A2 (en) * 1995-06-06 1996-12-12 Novartis Ag Methods for distinguishing metastatic and non-metastatic cancers, polynucleotides and polypeptides for use therein
GB9519275D0 (en) 1995-09-21 1995-11-22 Univ Dundee Substances and their therapeutic use
DE10229391A1 (de) * 2002-06-29 2004-01-29 Forschungszentrum Karlsruhe Gmbh METASTACHIP: ein Biochip zur Bestimmung des metastatischen Potentials von Tumoren
AU2005276231A1 (en) 2004-08-27 2006-03-02 Cyclacel Limited Purine and pyrimidine CDK inhibitors and their use for the treatment of autoimmune diseases
DK2580240T3 (en) 2010-06-14 2019-03-25 Lykera Biomed S A S100A4 ANTIBODIES AND THERAPEUTIC APPLICATIONS THEREOF

Also Published As

Publication number Publication date
EP0566571A1 (de) 1993-10-27
JP3398149B2 (ja) 2003-04-21
EP0566571B1 (de) 1997-05-07
CA2086829A1 (en) 1992-01-10
JPH06500018A (ja) 1994-01-06
DE69126038D1 (de) 1997-06-12
DE69126038T2 (de) 1997-09-25
EP0566571A4 (de) 1993-05-27
JP2003199589A (ja) 2003-07-15
WO1992000757A1 (en) 1992-01-23
JP3527733B2 (ja) 2004-05-17
DK0566571T3 (da) 1997-12-15

Similar Documents

Publication Publication Date Title
DE69126038D1 (de) Diagnose von krebs-metastasen durch das mts-1 gen
CA2042064A1 (en) C-erbb-2 external domain:gp75
CA2164498A1 (en) Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices
TR200200937T2 (tr) Yumurtalık kanseri tedavisi için bileşimler.
ATE229073T1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
ATE142108T1 (de) Monoklonaler antikörper gegen ein neues humanes tumor assoziiertes antigen
BR0112542A (pt) Composições e métodos papa a terapia e a diagnose de câncer ovariano
WO2001057182A3 (en) Nucleic acids, proteins, and antibodies
Bordes et al. Carcinoembryonic antigen (CEA) and related antigens in blood cells and hematopoietic tissues
SE8700805L (sv) Monoklonala antikroppar och antigen for icke-smacelligt humanlungkarcinom och vissa andra humankarcinom
WO2001002556A3 (de) Mittel zur diagnose, prognose und therapie maligner erkrankungen
AP2000001917A0 (en) Gene encoding labyrinthin, a marker for cancer.
ATE266203T1 (de) Methode zur identifizierung von tumorantigenen mit autoantikörpern in serum
Ikeda et al. Carcinoembryonic antigen (CEA) in stage IV gastric cancer as a risk factor for liver metastasis: a univariate and multivariate analysis
SE9500030D0 (sv) Method of determining metastatic potential of tumor cells
Patel et al. Significance of serum sialoglycoproteins in patients with lung cancer
DK0495910T3 (da) Fremstilling og anvendelse af humant nm23-H2-protein og derimod rettede antistoffer
Khan et al. In vivo determinations of labelling index of metastatic colorectal carcinoma and normal colonic mucosa using intravenous infusions of bromodeoxyuridine
Croce et al. Association of α 1 acidic glycoprotein and squamous cell carcinoma of the head and neck
Oehr et al. Tissue polypeptide antigen and specific TPA
Sasaki et al. Breast cancer markers: comparison between sialyltransferase and human mammary epithelial antigens (HME-Ags) for the detection of human breast tumors grafted in nude mice
Truax et al. A method for demonstrating probable synthesis of protein by bone marrow cells
Merrouche marker for interle~-2/interferon-responsive tumors. Can
Ljung Radiotherapy of prostatic adenocarcinoma, with reference to local cure, characterization of residual tumour cells with assessment of adverse effects.
Franzen A two-dimensional gel electrophoretic study of proteins in tumours of the lung and breast.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee